<DOC>
	<DOCNO>NCT00801281</DOCNO>
	<brief_summary>Evaluation event free survival ( EFS ) patient treat study chemotherapy induction program : R-CHOP compare standard R-CVP regimen response rate , time best response , PFS , OS , neutropenic fever rate , infection rate , change Ig level , change lymphocyte subpopulation count previously untreated indolent lymphoma patient need systemic treatment .</brief_summary>
	<brief_title>First-line R-CVP v R-CHOP Induction Immunochemotherapy Indolent Lymphoma R Maintenance .</brief_title>
	<detailed_description>Min . 3 , max . 8 induction cycle . Maintenance rituximab q . 2 month x 12/24 month , start 2 month last chemotherapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Histologically confirm : Follicular lymphoma grade 1 , 2 , 3a Marginal zone lymphoma , include MALT type Small lymphocytic lymphoma ( BM inv . &lt; 30 % ) Lymphoplasmacytic lymphoma Clinical stage IIIV ( Ann Arbor ) . Stage I allow bulky ( Ø &gt; 7 cm ) radiotherapy appropriate judgment treat physician Measurable lesion ( ) least one site Patients previously untreated Patients present symptom require treatment : Progressive disease Symptoms related tumor bulk Cytopenias relate bone marrow and/or spleen involvement B symptom Age ≥ 18 year Performance status &lt; /=2 Written inform consent Grade 3b FL Transformed lymphoma CNS involvement Patient take steroid &gt; 2 week last 4 week dose equivalent ≥ 20 mg prednisone Other malignancy Major surgery within 4 week Hb &lt; 8 g/dl , ANC &lt; 1.5 x 109/L , Plt &lt; 100 109/L unless due lymphoma Impairment renal function ( creatinine &gt; 1.5 x UNV ) liver function ( total bilirubin 1.5 x UNV , SGOT &gt; 2.5 x UNV due lymphoma Known infection , HBV , HCV ( acute &lt; 6 mo . chronic hepatitis ) HIV Serious underlie medical condition Life expectancy &lt; 6 month Known allergy murine protein</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Immunochemotherapy</keyword>
	<keyword>Induction therapy</keyword>
	<keyword>Maintenance therapy</keyword>
	<keyword>Follicular lymphoma grade 1,2,3a</keyword>
	<keyword>Marginal zone lymphoma , include MALT type</keyword>
	<keyword>Small lymphocytic lymphoma ( BM inv . &lt; 30 % )</keyword>
</DOC>